Neoadjuvant therapy is an essential part of high-risk stage III resectable melanoma management, with combination ...

Promising Triple Negative Breast Cancer Pipeline Therapies in the various stages of development include Nanosomal Docetaxel ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

A letter from the FDA rejecting Merck Sharpe & Dohme Corp.'s proposed label warning that its osteoporosis drug Fosamax could cause stress fractures doesn’t preempt state law claims alleging the ...

Supported by Merck Sharp and Dohme, a subsidiary of Merck (Rahway, NJ). Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the patients ...

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with ...

Belzutifan improved progression-free survival and objective response rate compared to everolimus in previously treated ...

He began his career in the pharmaceutical industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK subsidiary, advancing through different roles in the business around the world.

Shares of Sun Pharmaceutical Industries extended ... Sun Pharma has acquired the rights from Merck, Sharp & Dohme (MSD) to develop, manufacture, and commercialise Tedizolid Phosphate in India.

CY-101 well tolerated with early signs of clinical activity, especially in tumors with dysregulated Wnt/β-catenin signalling CY-101 granted Orphan Drug Designation in US for the treatment of ...

BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients.Promising efficacy data in combination with KEYTRUDA® (pembrolizumab) with partial responses in ...

LUND, SE / ACCESSWIRE / September 09, 2024 / BioInvent International (STO:BINV) BT-001 monotherapy showed stable disease and injected lesions shrinkage in advanced solid tumor patients. Promising ...